188 related articles for article (PubMed ID: 35083934)
41. Primary Care Prescription Drug Use and Related Actionable Drug-Gene Interactions in the Danish Population.
Lunenburg CATC; Hauser AS; Ishtiak-Ahmed K; Gasse C
Clin Transl Sci; 2020 Jul; 13(4):798-806. PubMed ID: 32166845
[TBL] [Abstract][Full Text] [Related]
42. Potentially actionable pharmacogenetic variants and symptom control medications in oncology.
Patel JN; Boselli D; Jandrisevits EJ; Hamadeh IS; Salem A; Meadors P; Walsh D
Support Care Cancer; 2021 Oct; 29(10):5927-5934. PubMed ID: 33758969
[TBL] [Abstract][Full Text] [Related]
43. Patient-provider communications about pharmacogenomic results increase patient recall of medication changes.
Borden BA; Lee SM; Danahey K; Galecki P; Patrick-Miller L; Siegler M; Sorrentino MJ; Sacro Y; Davis AM; Rubin DT; Lipstreuer K; Polonsky TS; Nanda R; Harper WR; Koyner JL; Burnet DL; Stadler WM; Kavitt RT; Meltzer DO; Ratain MJ; O'Donnell PH
Pharmacogenomics J; 2019 Dec; 19(6):528-537. PubMed ID: 30713337
[TBL] [Abstract][Full Text] [Related]
44. Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients.
Lewis JP; Backman JD; Reny JL; Bergmeijer TO; Mitchell BD; Ritchie MD; Déry JP; Pakyz RE; Gong L; Ryan K; Kim EY; Aradi D; Fernandez-Cadenas I; Lee MTM; Whaley RM; Montaner J; Gensini GF; Cleator JH; Chang K; Holmvang L; Hochholzer W; Roden DM; Winter S; Altman RB; Alexopoulos D; Kim HS; Gawaz M; Bliden KP; Valgimigli M; Marcucci R; Campo G; Schaeffeler E; Dridi NP; Wen MS; Shin JG; Fontana P; Giusti B; Geisler T; Kubo M; Trenk D; Siller-Matula JM; Ten Berg JM; Gurbel PA; Schwab M; Klein TE; Shuldiner AR;
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):203-210. PubMed ID: 31504375
[TBL] [Abstract][Full Text] [Related]
45. Economic Outcomes Following Combinatorial Pharmacogenomic Testing for Elderly Psychiatric Patients.
Jablonski MR; Lorenz R; Li J; Dechairo BM
J Geriatr Psychiatry Neurol; 2020 Nov; 33(6):324-332. PubMed ID: 31842673
[TBL] [Abstract][Full Text] [Related]
46. International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing.
Pereira NL; So D; Bae JH; Chavez I; Jeong MH; Kim SW; Madan M; Graham J; O'Cochlain F; Pauley N; Lennon RJ; Bailey K; Hasan A; Baudhuin LM; Bell MR; Lerman A; Goodman S; Mathew V; Farkouh M; Rihal CS
Pharmacogenet Genomics; 2019 Jun; 29(4):76-83. PubMed ID: 30724853
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness of cytochrome P450 2C19 *2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome.
Wang Y; Yan BP; Liew D; Lee VWY
Pharmacogenomics J; 2018 Jan; 18(1):113-120. PubMed ID: 28117433
[TBL] [Abstract][Full Text] [Related]
48. Pre-emptive pharmacogenomics implementation among polypharmacy patients 65 years old and older: a clinical pilot.
Uber R; Hayduk VA; Pradhan A; Ward T; Flango A; Graham J; Wright EA
Pharmacogenomics; 2023 Dec; 24(18):915-920. PubMed ID: 37965783
[No Abstract] [Full Text] [Related]
49. Effect of
Bergmeijer TO; Yasmina A; Vos GJA; Janssen PWA; Hackeng CM; Kelder JC; Verma SS; Ritchie MD; Gong L; Klein TE; Icpc Investigators ; de Boer A; Klungel OH; Ten Berg JM; Deneer VHM
Genes (Basel); 2020 Sep; 11(9):. PubMed ID: 32932966
[TBL] [Abstract][Full Text] [Related]
50. Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases.
Zhu Y; Swanson KM; Rojas RL; Wang Z; St Sauver JL; Visscher SL; Prokop LJ; Bielinski SJ; Wang L; Weinshilboum R; Borah BJ
Genet Med; 2020 Mar; 22(3):475-486. PubMed ID: 31591509
[TBL] [Abstract][Full Text] [Related]
51. Pharmacogenomic testing in oncology: a health system's approach to identify oncology provider perspectives.
Bhatt M; Peshkin BN; Kazi S; Schwartz MD; Ashai N; Swain SM; Smith DM
Pharmacogenomics; 2023 Nov; 24(16):859-870. PubMed ID: 37942634
[No Abstract] [Full Text] [Related]
52. Assessment of primary care practitioners' attitudes and interest in pharmacogenomic testing.
Smith DM; Namvar T; Brown RP; Springfield TB; Peshkin BN; Walsh RJ; Welsh JC; Levin B; Brandt N; Swain SM
Pharmacogenomics; 2020 Oct; 21(15):1085-1094. PubMed ID: 32969759
[No Abstract] [Full Text] [Related]
53. The effect of
Tan K; Lian Z; Shi Y; Wang X; Yu H; Li M; Tian J; Ge Y
Per Med; 2019 Jul; 16(4):301-312. PubMed ID: 31322488
[No Abstract] [Full Text] [Related]
54. Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population.
Shen DL; Wang B; Bai J; Han Q; Liu C; Huang XH; Zhang JY
J Cardiovasc Pharmacol; 2016 Mar; 67(3):232-6. PubMed ID: 26727381
[TBL] [Abstract][Full Text] [Related]
55. Personalized antiplatelet therapy in patients with coronary artery disease undergoing percutaneous coronary intervention: A network meta-analysis of randomized clinical trials.
Kheiri B; Abdalla A; Osman M; Barbarawi M; Zayed Y; Haykal T; Chahine A; Bachuwa G; Hassan M; Bhatt DL
Catheter Cardiovasc Interv; 2019 Aug; 94(2):181-186. PubMed ID: 30628754
[TBL] [Abstract][Full Text] [Related]
56. Using pharmacogenetics in primary care.
Murfin M
JAAPA; 2019 Aug; 32(8):17-21. PubMed ID: 31290773
[TBL] [Abstract][Full Text] [Related]
57. Association of Pharmacogenomic Phenotypes in CYP2D6, CYP2C9, CYP2C19, and CYP3A5 on Polypharmacy in Veterans.
Krulikas L; Bates J; Chanfreau C; Coleman H; Dalton S; Voora D
Clin Pharmacol Ther; 2024 May; ():. PubMed ID: 38775021
[TBL] [Abstract][Full Text] [Related]
58. CYP2C19 Genotype is an Independent Predictor of Adverse Cardiovascular Outcome in Iraqi Patients on Clopidogrel After Percutaneous Coronary Intervention.
Mohammad AM; Al-Allawi NAS
J Cardiovasc Pharmacol; 2018 Jun; 71(6):347-351. PubMed ID: 29554005
[TBL] [Abstract][Full Text] [Related]
59. Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy.
Gross L; Trenk D; Jacobshagen C; Krieg A; Gawaz M; Massberg S; Baylacher M; Aradi D; Stimpfle F; Hromek J; Vogelgesang A; Hadamitzky M; Sibbing D; Geisler T
Thromb Haemost; 2018 Sep; 118(9):1656-1667. PubMed ID: 30103241
[TBL] [Abstract][Full Text] [Related]
60. The Prevalence and Features of Medications With Actionable Pharmacogenomic Biomarkers Prescribed to Kidney Transplant Recipients.
Chang YL; Hsiao TH; Wu MF; Chen CH
Transplant Proc; 2023 May; 55(4):862-866. PubMed ID: 37127518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
